20-F: Galapagos Pivots to BD, Exits Cell Therapy, Boosts Cash

Galapagos NV announced a significant strategic shift, winding down its cell therapy operations and small molecule discovery programs to focus on business development-led pipeline expansion in oncology and immunology, backed by a strong cash position.

Summary

• Galapagos NV is undergoing a major strategic transformation, shifting from internal R&D to a business development-led model focused on acquiring, partnering, or licensing clinically de-risked assets in oncology and immunology & inflammation (I&I).
• The company announced its intention in October 2025 to wind down all cell therapy activities, a decision initiated in January 2026, impacting approximately 365 employees and closing sites in Leiden, Basel, Princeton, Pittsburgh, and Shanghai.
• Small molecule discovery programs were discontinued in January 2025, impacting around 300 positions and closing the site in France.
• The remaining clinical pipeline consists solely of GLPG3667, a TYK2 inhibitor in Phase 2 trials for dermatomyositis (DM) and systemic lupus erythematosus (SLE).
• The GALARISSO DM study for GLPG3667 met its primary endpoint, showing a statistically significant clinical benefit in Total Improvement Score (TIS) at Week 24 (p=0.0848).
• The GALACELA SLE study for GLPG3667 did not meet its primary endpoint of SRI-4 response at Week 32, but showed numerical improvements on several secondary endpoints, particularly skin-related outcomes.
• Net profit for the year ended December 31, 2025, was €320.9 million, primarily driven by the release of €1,069.0 million in deferred income related to the Gilead Option, License and Collaboration Agreement (OLCA).
• Cash and cash equivalents, and financial investments totaled €2,998.0 million as of December 31, 2025.
• The company plans to propose a name change to Lakefront Biotherapeutics NV at the April 2026 Extraordinary General Meeting.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a pivotal moment for Galapagos NV, marked by strong reported financial performance driven by a one-time revenue event and a decisive strategic shift towards a business development model. While the exit from cell therapy and small molecule discovery introduces near-term operational challenges and asset concentration risk, the substantial cash reserves and new leadership position the company for potential future growth through external innovation.

Positives

• Reported a net profit of €320.9 million for the year ended December 31, 2025, a significant increase from €74.1 million in 2024.
• The net profit was primarily driven by the release of €1,069.0 million in deferred income related to the Gilead OLCA.
• Maintains a robust financial position with €2,998.0 million in cash and financial investments as of December 31, 2025.
• The GLPG3667 GALARISSO DM study met its primary endpoint, demonstrating statistically significant clinical benefit (p=0.0848) and a favorable safety profile.
• Ongoing royalty streams and earn-outs from the Jyseleca business are expected to continue into the mid-2030s.
• Gilead, a major shareholder, has expressed willingness to renegotiate OLCA terms to support value-accretive transactions, indicating continued partnership flexibility.
• A new leadership team with extensive business development experience has been appointed to drive the new strategic direction.

Negatives

• All cell therapy activities are being wound down, impacting approximately 365 employees and leading to the closure of sites in Leiden, Basel, Princeton, Pittsburgh, and Shanghai.
• Small molecule discovery programs were discontinued, impacting around 300 positions and closing the site in France.
• The GLPG3667 GALACELA SLE study did not meet its primary endpoint at Week 32, indicating a setback for this program.
• Expects to incur operating losses for the foreseeable future, given that the significant deferred revenue recognition from the Gilead OLCA is a one-time event.
• Recorded a substantial impairment loss of €228.1 million in 2025 due to the wind-down of cell therapy activities.
• Incurred restructuring provisions of €29.2 million for early termination of small molecule collaboration agreements and €16.3 million for cell therapy contracts.
• The clinical collaboration agreement with Adaptimmune was terminated, resulting in the loss of the option to an exclusive license for uza-cel.
• The company will be substantially dependent on the success of GLPG3667 as its only product candidate in development until new assets are acquired or developed.

Risks

• Limited operating history of the current business model makes future prospects and financial results difficult to assess.
• Anticipation of significant operating losses for the foreseeable future after the 2025 deferred revenue recognition.
• Requirement for substantial additional funding, which may not be available on acceptable terms or at all.
• Corporate transformation, including pipeline prioritization and headcount reduction, may not be successful or yield desired results.
• Wind-down of cell therapy activities is subject to various risks and uncertainties and may not be completed timely or favorably, with potential costs exceeding estimates.
• Unsuccessful identification and implementation of strategic transactions, or failure to realize anticipated benefits, or integration difficulties.
• Need to negotiate amended terms of the OLCA with Gilead for strategic transactions, with no assurance of favorable terms.
• Significant competition for strategic transaction opportunities due to limited resources compared to larger competitors.
• Substantial dependence on the success of GLPG3667 as the only product candidate in development following the wind-down of cell therapy activities.
• Lengthy, time-consuming, and unpredictable regulatory approval processes for product candidates.
• Interim, topline, or preliminary data from preclinical/clinical trials may change, subject to audit and verification.
• Differing perspectives of local regulatory authorities in global clinical trials could negatively impact approvals or labels.
• Ongoing obligations and regulatory review post-approval may result in significant expenses, labeling restrictions, or market withdrawal.
• Clinical development is lengthy, expensive, and uncertain, with earlier results not predictive of future outcomes.
• Significant competition for drug discovery and development efforts.
• Product candidates may cause undesirable side effects, delaying approval or limiting commercial profile.
• Reliance on third parties (Gilead, CROs, manufacturers) for development, commercialization, and supply, with risks of non-performance or delays.
• Inability to adequately protect proprietary rights could lead to competitive decline.
• Exposure to claims by third parties asserting ownership or commercial rights to inventions or obligations for compensatory payments.
• Risk of employees/consultants wrongfully using or disclosing confidential information/trade secrets.
• Intellectual property litigation can be costly and time-consuming, with unfavorable outcomes harming the business.
• Issued patents could be found invalid or unenforceable if challenged.
• Inability to protect trademarks and trade names could hinder name recognition.
• Inability to protect intellectual property or maintain data confidentiality/integrity due to cyber-attacks or other events.
• Future success depends on ability to retain and attract qualified personnel, especially given recent workforce reductions.
• International operations subject the company to various risks (currency fluctuations, adverse tax consequences, regulatory changes, political instability).
• Inability to use tax loss carryforwards or benefit from favorable tax legislation could adversely affect financial condition.
• Shareholders outside Belgium may face double withholding taxation on dividends.
• Belief that the company was a PFIC for U.S. federal income tax purposes for 2025 and may be in future years, leading to adverse U.S. tax consequences for certain U.S. holders.
• Risk of being forced to repay technological innovation grants if contractual obligations are not met.
• Requirements of being a U.S. public company may strain resources and divert management's attention.
• Market price of ADSs subject to wide fluctuations.
• Increased risk of securities class action litigation and shareholder activism.
• Concentrated share ownership may delay or prevent a change of control.
• Fluctuations in EUR/USD exchange rate may increase risk for ADS holders.
• Lack of research or unfavorable research from analysts could cause stock price decline.
• No present intention to pay dividends, making share price appreciation the only return opportunity.
• Belgian corporate law may offer more limited shareholder rights than U.S. law.
• Belgian takeover provisions may make a takeover difficult.
• Limitations on transfer of ADSs and withdrawal of underlying shares.
• Exemption as a foreign private issuer limits information available to holders.
• Loss of foreign private issuer status could result in significant additional cost and expense.
• Difficulty for investors outside Belgium to serve process or enforce foreign judgments.
• Unforeseen or catastrophic events (natural disasters, epidemics, geopolitical issues) could disrupt operations.
• Increasing use of social media platforms presents risks and challenges.

Future Outlook

The company expects to incur operating losses for the foreseeable future after the one-time deferred revenue recognition in 2025. It anticipates being cash flow neutral to positive by the end of 2026, excluding business development activities and currency fluctuations, with an estimated €2.775 billion to €2.850 billion in cash, cash equivalents, and financial investments by December 31, 2026. Operational cash outflow of up to €50 million is expected in Q1 2026 for the cell therapy wind-down, along with a one-time restructuring cash impact of €125 million to €175 million in 2026. Costs for the ongoing GLPG3667 TYK2 program are projected to be up to €40 million in 2026. The company is evaluating strategic options for GLPG3667, including potential partnerships for DM development and assessing requirements for a Phase 3 program. Final Week 48 data from the GALACELA SLE study is expected in Q2 2026. The company will continue to manage non-cell therapy activities and plans to propose a name change to Lakefront Biotherapeutics NV at the April 2026 EGM, signaling a focus on disciplined capital deployment and value-accretive opportunities in oncology and I&I, and potentially other fields.

Management Comments

• "Our transformation is well underway. We will deploy capital with discipline and focus, prioritizing value-accretive opportunities that align with our operational strengths and long-term ambitions."
• "With a highly motivated new leadership team with unparalleled dealmaking experience, a strong balance sheet, and a clear strategic vision in place, we believe we are well positioned to build a pipeline capable of delivering meaningful medicines to patients."

Industry Context

StockSavvy.ai notes that Galapagos NV's strategic pivot reflects a broader trend in the biotechnology sector where companies with strong cash positions and mature pipelines often re-evaluate their R&D models. The shift from internal discovery and cell therapy to a business development-led approach, particularly in oncology and immunology, aligns with industry movements towards external innovation and disciplined capital allocation, especially for companies seeking to de-risk their portfolios and leverage existing partnerships like the one with Gilead. The proposed name change to Lakefront Biotherapeutics NV also signals a clear rebranding effort to align with this new strategic direction, aiming to enhance agility and decision-making in a competitive market.

Comparison to Industry Standards

• In Dermatomyositis (DM), GLPG3667 faces competition from Octagam (IVIg) by Octapharma (FDA approved in 2021), and brepocitinib (oral JAK1/TYK2; Proviant) which met its Phase 3 primary endpoint in September 2025 with a regulatory filing planned for early 2026.
• Other Phase 3 compounds for DM expected to launch before the end of the decade include dazukibart (anti-IFN; Pfizer), anifrolumab (Saphnelo; anti-IFN; AstraZeneca), and efartigimod (anti-FcRn; Argenx).
• In Systemic Lupus Erythematosus (SLE), GLPG3667 competes with Belimumab (Benlysta) (anti-BAFF) from GSK and anifrolumab (Saphnelo) (anti-IFN) from AstraZeneca, both approved as add-on therapies.
• Over 10 products are in Phase 3 clinical development for SLE, predominantly injectable therapies for advanced disease, with oral therapies like deucravacitinib (SotyktuTM) (TYK2) from BMS, upadacitinib (RinvoqTM) (JAK) from Abbvie, and cenerimod (S1P1) from Idorsia/Viatris also in development.
• The company's shift to a business development model is comparable to other biotech firms that leverage capital and expertise to acquire de-risked assets rather than solely relying on costly and high-risk internal discovery.

Management Changes

Corporate Governance

Legal Proceedings

• Not presently a party to any legal proceedings that would individually or collectively have a material adverse effect on business, results of operations, financial condition, or cash flows.
• NovAliX initiated certain claims after early termination of collaboration; a settlement agreement was reached in 2026, in line with the restructuring provision.
• Mr. Nodelman and EcoR1 Capital LLC were fined €3.0 million and €7.0 million respectively by the French AMF for market abuse regulation and reporting obligations violations; they submitted an appeal in February 2025.

Related Party Transactions

• Gilead Sciences, Inc. is a significant shareholder (25.35% as of March 11, 2026) and a key collaboration partner through the Option, License and Collaboration Agreement (OLCA) from July 2019.
• Galapagos received a $3.95 billion upfront payment and a $1.1 billion (€960.1 million) equity investment from Gilead in 2019 as part of the OLCA.
• OLCA amendments in 2025 led to the derecognition and release of €1,069.0 million in deferred income as revenue.
• Gilead waived its rights under the OLCA for all small molecule R&D activities (January 2025) and cell therapy R&D activities (July 2025), subject to certain payments and royalties.
• Royalty income from Gilead on Jyseleca sales outside Europe amounted to €12.2 million in 2025, €10.6 million in 2024, and €9.5 million in 2023.
• The Subsequent Warrant B, approved by EGM on April 30, 2024, allows Gilead to increase its ownership up to 29.9%.
• Board meetings in 2025 and 2026 reported potential conflicts of interest for Gilead representatives on the Board regarding compensation and related-party transactions with Gilead.
• The Jyseleca business was transferred to Alfasigma S.p.A. on January 31, 2024, for a €50 million upfront payment, potential milestone payments totaling €120 million, and mid-single to mid-double-digit earn-outs on European sales.
• Galapagos contributed €15 million in 2024 and €25 million in 2025 to Alfasigma for Jyseleca-related development activities.
• A contingent consideration receivable from Alfasigma related to future earn-outs and sales milestones was valued at €54.7 million as of December 31, 2025.
• In April 2025, Galapagos sold multiple small molecule immunology and oncology assets to Onco3R Therapeutics and participated in Onco3R's start-up capital via a €20 million convertible loan facility.
• The contingent consideration from Onco3R was valued at zero as of December 31, 2025, due to the early stage of the transferred assets.
• The integrated drug discovery collaboration with NovAliX, entered July 1, 2023, with a €73.8 million service commitment, had the majority of its work orders terminated in March 2025, leading to a settlement agreement in 2026.
• The clinical collaboration agreement with Adaptimmune, including a $70.0 million upfront exclusivity payment and $15.0 million R&D funding, was assigned to USWM CT, LLC in July 2025 and will be terminated effective April 16, 2026.
• Executive Committee members' compensation includes fixed remuneration, variable cash bonuses, and long-term incentives (RSUs, subscription rights).
• Board members' compensation includes fixed cash fees and equity-based remuneration (shares acquired with net cash compensation).
• Severance compensation for Executive Committee members in case of a change of control includes immediate vesting of equity awards and 9-12 months' base salary.

Stakeholder Impact

• Shareholders face potential for long-term value creation through the new strategic business development model, but also dilution risk from future capital raises and share price volatility due to strategic shifts and R&D outcomes. No dividends are expected in the foreseeable future.
• Employees are significantly impacted by workforce reductions (approximately 300 in January 2025 and 365 in January 2026) due to program discontinuations and the cell therapy wind-down, leading to potential reduced morale and attrition.
• Customers and patients may see a shift in future treatment options due to the discontinuation of certain R&D programs, while the development of GLPG3667 in DM and SLE continues.
• Collaboration partners, particularly Gilead, are affected by amendments to existing agreements reflecting Galapagos' strategic changes, with Gilead's continued involvement and flexibility being crucial for future transactions.
• Suppliers and creditors are impacted by early termination of contracts due to restructuring and wind-down, leading to provisions for liabilities and potential renegotiations.
• Regulatory bodies will continue to oversee compliance with clinical trials, manufacturing, and data privacy regulations, especially with the changes in R&D focus and site closures.

Next Steps

• Complete the wind-down of cell therapy activities by the end of Q3 2026.
• Evaluate all strategic options for GLPG3667, including potential partnerships and business development opportunities to accelerate development in DM.
• Assess funding and capability requirements for running a Phase 3 program for GLPG3667 in DM.
• Obtain final Week 48 data from the GALACELA SLE study in Q2 2026 to determine next steps for the SLE program.
• Pursue transformative business development opportunities to acquire, partner, or license new product candidates.
• Propose a name change to Lakefront Biotherapeutics NV at the April 2026 Extraordinary General Meeting.
• Comply with local Pillar 2 requirements for financial years beginning on January 1, 2026.
• Conduct an evaluation of the Board of Directors and its committees in 2026.
• Anticipated last patient visit for ATALANTA-1 and PAPILIO-1 studies for the end of May 2026, with patients rolling over into the long-term HESPERIA study for safety monitoring.
• Tania Philipp joins as Chief Human Resources Officer and member of the Management Committee effective March 4, 2026.
• Mr. Jérôme Contamine's mandate as Chair and Board member will end immediately after the AGM of April 28, 2026.
• Mr. Gino Santini is proposed to be appointed by the Board of Directors as the new Chair of the Board of Directors, subject to shareholder approval.

Key Dates

Recommendation

The company is undergoing a significant and necessary strategic transformation, exiting high-cost, high-risk areas like cell therapy and small molecule discovery to focus on a business development-led model. While the reported net profit for 2025 is strong due to a one-time deferred revenue release, the future outlook anticipates operating losses. The substantial cash reserves provide a strong foundation for the new strategy, and positive Phase 2 data for GLPG3667 in DM is encouraging. However, the execution risk of the new business development strategy, dependence on a single clinical asset (GLPG3667), and the ongoing costs and uncertainties associated with the wind-down and workforce reductions warrant a cautious 'hold' stance until there is clearer evidence of successful pipeline rebuilding and sustained profitability.

Keywords

Biotechnology, Pharmaceuticals, Oncology, Immunology, Drug Development, Clinical Trials, R&D, Strategic Transformation, Cell Therapy, Small Molecules, GLPG3667, TYK2 inhibitor, Dermatomyositis, Systemic Lupus Erythematosus, Gilead, SEC Filing, Financial Results, Corporate Governance, Risk Management, Belgium, Nasdaq